FRIDAY, July 1, 2022 (HealthDay News) — Vaccination protects in opposition to extreme COVID-19 amongst individuals with obese and weight problems, with the magnitude of safety much like that of wholesome weight individuals, in accordance with a research printed on-line June 30 in The Lancet Diabetes & Endocrinology.
Carmen Piernas, Ph.D., from the University of Oxford within the United Kingdom, and colleagues carried out a inhabitants-primarily based cohort research involving 9,171,524 individuals aged 18 years or older between Dec. 8, 2020, and Nov. 17, 2021, with accessible knowledge on physique mass index (BMI).
The researchers discovered that 19.2 p.c of the entire research pattern was unvaccinated and three.1, 52.6, and 25.0 p.c had one, two, and three vaccine doses, respectively. Uptake of two or three doses was greater than 80 p.c amongst these with obese or weight problems amongst individuals aged 40 years or older, in contrast with 70 to 83 p.c amongst underweight individuals. Protection in opposition to extreme COVID-19 illness was excessive after 14 days or extra from the second dose for hospital admission and loss of life. Significant linear associations had been seen between BMI and COVID-19 hospitalization and loss of life after the primary dose within the vaccinated cohort, and J-formed associations had been seen after the second dose.
“Our outcomes present reassurance to individuals with weight problems that COVID-19 vaccines are equally as efficient for them as for individuals with a decrease BMI, and that vaccination considerably reduces their threat of extreme sickness if they’re contaminated with COVID-19,” Piernas mentioned in a press release. “These knowledge additionally spotlight the necessity for focused efforts to extend vaccine uptake in individuals with a low BMI, the place uptake is presently decrease than for individuals with a better BMI.”
Several authors disclosed monetary ties to the pharmaceutical trade.
Abstract/Full Text
Editorial
Source link